Bal Pharma Limited

BALPHARMA

INE083D01012

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:49 2024-04-29 am EDT			5-day change	1st Jan Change
101.1 ^INR	+0.96%		+2.43%	+0.64%

Feb. 12	Bal Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI
2023	Bal Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	CI

Bal Pharma Limited Appoints Kotian Chittananda Damodar as Additional Director (Non Independent)

May 30, 2022 at 08:45 am EDT

The board of directors of Bal Pharma Limited at its meeting held on May 30, 2022, appointed Mr. Kotian Chittananda Damodar (DIN # 09613054) as Additional Director (Non Independent) of the Company.

Latest news about Bal Pharma Limited

Bal Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 12	CI
Bal Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 08	CI
Bal Pharma Limited Approves Dividend	23-09-25	CI
Bal Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-11	CI
Bal Pharma Limited Appoints Abdul Basith as Company Secretary and Compliance Officer	23-07-17	CI
Bal Pharma Limited Appoints Nicola Neeladri as Additional Director	23-06-01	CI
Bal Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-29	CI
Bal Pharma Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	23-05-29	CI
Bal Pharma Limited Recommends Dividend	23-05-29	CI
Bal Pharma Limited Announces Resignation of Mrs.Preeti Singh as Company Secretary	23-05-15	CI
Acuite Keeps BBB- Rating on Bal Pharma's Bank Loans; Outlook Stable	23-04-25	MT
Bal Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-06	CI
Bal Pharma CFO Resigns	22-11-24	MT
Bal Pharma Limited Announces Resignation of Mr. G. Rengarajan as Chief Financial Officer	22-11-24	CI
Bal Pharma Limited Reports Earnings Results for the Half Year Ended September 30, 2022	22-11-14	CI
Bal Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-14	CI
Bal Pharma Limited Declares Dividend	22-09-19	CI
Bal Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-11	CI
Bal Pharma Limited Appoints Kotian Chittananda Damodar as Additional Director (Non Independent)	22-05-30	CI
Bal Pharma Limited Recommends Dividend	22-05-30	CI
Acuite Upgrades Rating on Bal Pharma's Fund-Based Financing to BBB-; Lowers Outlook to Stable	22-02-22	MT
Bal Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-10	CI
ICRA Maintains BB+ Rating on Bal Pharma's Long-Term Bank Financing; Raises Outlook to Positive	21-12-21	MT
Bal Pharma's Consolidated Profit Soars in Fiscal Q2	21-12-09	MT
Bal Pharma Limited Declares Dividend for the Year Ended March 31, 2021	21-09-27	CI

Bal Pharma Limited is a fully integrated pharmaceutical company. The Company is engaged in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (API). It is specialized in bulk actives, prescription drugs, generics and pharma intermediates. Its focused therapeutic areas are anti-diabetes, anti-histamine, anti-inflammatory, acne treatment, gastroenterology, cardiology, and dermatology. It offers a range of APIs, which includes antihistamine, platelet inhibitor, anti-diabetic, anti-convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, and acne treatment. Its finished formulation products cover dosage forms, such as tablets, capsules, syrups, suspensions, IV infusions, ophthalmic, creams and ointments. The Company offers a range of natural medicine, which includes ANARSHA, ASHWAMED, AYURFINE, AYURFINE FORTE, AYURSULIN, IMMUWIN, LIPIVED, MENOLEAP CAPSULES, MENOLEAP SYRUP, PROLIFE, and BALPRO SYRUP.

Sector

Pharmaceuticals

Calendar

2024-05-27 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BAL PHARMA LIMITED	+0.64%	18.85M
ELI LILLY AND COMPANY	+26.47%	661B
NOVO NORDISK A/S	+26.74%	566B
JOHNSON & JOHNSON	-6.33%	352B
MERCK & CO., INC.	+19.35%	332B
ABBVIE INC.	+4.23%	283B
ASTRAZENECA PLC	+13.43%	231B
NOVARTIS AG	+4.71%	200B
ROCHE HOLDING AG	-9.53%	195B
AMGEN INC.	-4.04%	145B